KR-27452
KR-27452 is a selective and orally active PI4KIIIβ inhibitor with an IC50 of 0.026 μM, while showing no activity against PI4KIIIα (IC50 >10 μM) . KR-27452 specifically binds to and inhibits PI4KIIIβ, leading to reduced viral replication in cells. KR-27452 exhibits strong antiviral activity against human rhinovirus (RVs) and Coxsackievirus (COXs). KR-27452 can be used for the research of infection.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C24H27N3O4S
- Molecular Weight:453.55
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
|
PI4KIIIβ 0.026 μM (IC50) |
KR-27452 (Compound 2e) exhibits EC50 of 0.236-0.813μM against RV-A and 0.104-0.664 μM against RV-B in H1HeLa cells, with CC50 >100 μM and SI >123[1].
KR-27452 has EC50 of 0.118 μM against RV-C15 with SI >85 in HeLa-CDHR3 cells[1].
KR-27452 shows EC50 of 0.28-0.981μM against COX B1-B6 in H1HeLa cells, with CC50 >100 μM and SI >102[1].
KR-27452 (1-10 μM, 24 h) dose-dependently inhibits plaque formation in RV14-infected H1HeLa cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 453.55
-
Formel C24H27N3O4S
-
SMILES
O=C(N(CCCO)C)C1=CC(C2=C(C)N=C(NC(CC3=CC=CC=C3)=O)S2)=CC=C1OC
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)